ArticleInternational journal of general medicine2025
Acupoint Catgut Embedding at Stellate Ganglion Combined with Oral Mecobalamin Versus Mecobalamin Monotherapy in Managing Taxane-Induced Peripheral Neurotoxicity: A Clinical Observational Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Taxane-induced peripheral neurotoxicity (TIPN) severely impacts the quality of life of patients and worsens over time with cumulative drug exposure. This study aims to evaluate the efficacy and safety of Stellate Ganglion Catgut Embedding (SGCE) therapy in treating TIPN patients, exploring a novel approach to managing TIPN. Patients and Methods: The study was conducted from June 2023 to June 2024 at the Second Affiliated Hospital of Harbin Medical University. Patients (at least two cycles of taxane treatment, including albumin-bound paclitaxel, paclitaxel, docetaxel, etc) were divided into methylcobalamin (MeCbl, n=25) and SGCE (n=21) groups. The former received oral methylcobalamin therapy, while the SGCE group underwent Stellate Ganglion Blockade with Catgut Implantation combined with oral methylcobalamin therapy. Neurotoxicity was assessed using the EORTC QLQ-CIPN15 and FACT/GOG-Ntx scales, with patient quality of life evaluated using the FACT-G scale. Comprehensive outcomes would be assessed on the day of treatment (SGCE or MeCbl treatment) and at the 1st and 3rd weeks post-treatment for all participants. Adverse events were assessed using the CTCAE scales. Results: The principal findings revealed that according to the EORTC QLQ-CIPN15 sensory, motor, overall scores and FACT/GOG-Ntx scale scores, there were significant decreases in the SGCE group compared to the MeCbl group after 3 weeks of treatment ( Conclusion: SGCE group produced a more pronounced improvement in symptoms among TIPN patients compared to MeCbl group, enhanced the quality of life of the patients compared with the pre-treatment period, this improvement could be linked to SGCE. Moreover, the patients did not show significant adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.